A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis.
Qian J, Ma C, Waterbury QT, Zhi X, Moon CS, Tu R, Kobayashi H, Wu F, Zheng B, Zeng Y, Zheng H, Ochiai Y, White RA, Harle DW, LaBella JS, Zamechek LB, ZhongMing Hu L, Moy RH, Han AS, Daugherty BL, Lederman S, Wang TC.
Qian J, et al. Among authors: zeng y.
Cancer Cell. 2025 Jun 21:S1535-6108(25)00256-9. doi: 10.1016/j.ccell.2025.06.006. Online ahead of print.
Cancer Cell. 2025.
PMID: 40578360